Holocene Advisors
REGN icon

Holocene Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Holocene Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-460,723
Closed -$356M – 944
2025
Q4 		$356M Buy
460,723
+308,990
+204% +$210M 0.75% 27
2025
Q3 		$85.3M Buy
+151,733
New +$85.8M 0.19% 127
2024
Q2 		– Sell
-81,857
Closed -$78.8M – 826
2024
Q1 		$78.8M Sell
81,857
-278,623
-77% -$265M 0.29% 109
2023
Q4 		$317M Buy
360,480
+182,727
+103% +$150M 1.23% 6
2023
Q3 		$146M Buy
177,753
+16,891
+11% +$13.3M 0.64% 46
2023
Q2 		$116M Buy
160,862
+32,613
+25% +$25.1M 0.49% 67
2023
Q1 		$105M Buy
128,249
+56,073
+78% +$42.3M 0.52% 66
2022
Q4 		$52.1M Buy
+72,176
New +$53.3M 0.32% 104
2021
Q1 		– Sell
-1,498
Closed -$724K – 924
2020
Q4 		$724K Buy
+1,498
New +$809K ﹤0.01% 595
2020
Q3 		– Sell
-122,952
Closed -$76.7M – 770
2020
Q2 		$76.7M Buy
+122,952
New +$69.8M 0.67% 47
2018
Q2 		– Sell
-752
Closed -$259K – 703
2018
Q1 		$259K Sell
752
-1,613
-68% -$561K 0.01% 426
2017
Q4 		$889K Buy
+2,365
New +$958K 0.02% 217

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Holocene Advisors's REGN Position: Q1 2026 in Review

Holocene Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 460,723 shares — an estimated $356M sold.

Holocene Advisors first reported a position in REGN in Q4 2017 and held it in 12 quarters. The position peaked at $356M in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Holocene Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Holocene Advisors sold 460,723 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $356M.
  • Holocene Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 12 quarters.
  • Holocene Advisors's Regeneron Pharmaceuticals position peaked at $356M in Q4 2025.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.